PEIJIA-B (09996) announced its 2025 annual performance, achieving revenue of approximately 700 million to 720 million yuan, a year-on-year growth of about 13.7-17.0%.

PEIJIA-B(09996) announced annual performance as of December 31, 2025 (reporting period), with the Group achieving revenues of approximately RMB 700 million to 720 million, a year-on-year growth of around 13.7-17.0%. The continuous revenue growth of the Group is mainly attributed to the strong performance of all three product lines in the neurointervention business; and the continuous expansion of market share in the China Transcatheter Aortic Valve Replacement (TAVR) market, mainly driven by the successful launch of the high-end TaurusMax 3D adjustable TAVR system. All three product lines in the neurointervention business recorded steady revenue growth, reflecting the strong performance of their respective core products. The main driving factors were the increase in revenue from vascular access products, mainly benefiting from the continuous expansion in sales of high-performance DCwire microguidewire, driving rapid market share increase; hemorrhagic products benefited from the successful launch of the YonFlow blood flow-guided mesh stent, driving revenue growth in this product line; ischemic products' revenue growth was mainly attributed to the increased sales of Syphonet retrieval stents and Tethys AS thrombectomy catheters. In the ischemic product portfolio, despite the sales price adjustment of balloon dilation catheters after centralized procurement implementation in the second half of 2025, sales volume increased significantly, especially for Fastunnel delivery balloon dilation catheters, maintaining overall revenue stability compared to 2024. During the reporting period, the Group's commercialized TAVR product portfolio (including TaurusOne, TaurusElite, and TaurusMax TAVR systems used nationwide for treating aortic valve stenosis, as well as the TrilogyTM transcatheter heart valve system used in Hong Kong and Taiwan for treating aortic valve regurgitation) was adopted in approximately 130 new hospitals, covering over 780 hospitals as of December 31, 2025. A total of approximately 3,900 units were implanted during the reporting period, with a 14.4% annual growth rate, significantly higher than the overall market growth rate. With the registration application of the TaurusTrio transcatheter aortic valve system approved by the National Medical Products Administration in December 2025, the company expects to fully commercialize in the Chinese aortic valve regurgitation market.